b'system would require significant additional time andmisleading statements and failed to disclose that (1) the investment, Boston Scientific would retire the LOTUSLOTUS Edge delivery system was dysfunctional, threat-Edge immediately. The same day, Boston Scientificsening the continued viability of the product line, and stock fell almost 8%. (2) Boston Scientific materially overstated the LOTUS On December 4, 2020, a Boston Scientific investorEdges continued commercial viability and profitability. filed a putative class action complaint, originally in theOn January 4, 2021, the court transferred the case to Eastern District of New York, against Boston Scientificthe District of Massachusetts. The statutory lead plain-and two of its officers, asserting claims under Sectionstiff process is underway, and lead plaintiff motions were 10(b) and 20(a) and Rule 10b-5 of the 1934 Act. Thefiled in early February.complaint alleges that defendants made false and 21'